Asset profile
MRX-2843
Small molecule
Evidence outlook · results not reported
NCT04946890 · Acute Myeloid Leukemia Leukemia
The lead study uses a design that frequently fails to replicate under controlled conditions, and its results have not been reported. This tier describes the design, not an outcome.
NCT04946890: This is an open-label, single-group dose-escalation study without a control arm, so it can characterize side effects and dosing but cannot show whether the drug improves outcomes compared with no treatment or another therapy. No results have been posted yet.
Also in development:Non-Small Cell Lung Cancer · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
120 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 120 same-indication; 99 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| MRX-2843: this drug | Phase 1/2 | Small molecule | Flt3/MerTK | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| ASTX727 | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK |
…and 105 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.